ArticleJCO oncology practice2025
Treatment Patterns, Trends, and Outcomes of Neoadjuvant Chemotherapy Use Among Patients With Early-Stage Invasive Triple-Negative Breast Cancer.
Article in JCO oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pathological assessment of tumour beds in breast excisions post-neoadjuvant therapy: a retrospective cohort study.Histopathology · 2026Article
- Fertility preservation using controlled ovarian stimulation in breast cancer: a comparative study of neoadjuvant and adjuvant settings.Journal of assisted reproduction and genetics · 2026Article
- Impact of bilateral surgery on time to treatment in patients with breast cancer undergoing mastectomy - a retrospective cohort study.BMC cancer · 2025Article
- Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer.NPJ breast cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTriple-negative breast cancer (TNBC) is a clinically aggressive subtype associated with poorer survival outcomes. We examined the patterns and trends in neoadjuvant chemotherapy (NACT) use, pathologic complete response (pCR), and overall survival (OS). Furthermore, we evaluated the association between pCR and OS in a large cohort of patients.
methodsPatients aged 18 years and older with stage I-III TNBC diagnosed between 2010 and 2021 were identified in the National Cancer Database. Trends in NACT use, pCR, and OS were assessed using the Cochran-Armitage test for time trends. Multivariable logistic regression was used to evaluate the factors associated with NACT use and pCR. The impact of pCR on OS was examined using a multivariable Cox proportional hazards model with propensity score (PS) adjustment and matching.
resultsThe rate of NACT receipt increased from 19.1% to 56.4% (
conclusionThe use of NACT among patients with TNBC has dramatically increased in the past decade. Although TNBC is more prevalent in Black patients, they were less likely to be treated with NACT and less likely to achieve a pCR. Further research is needed to elucidate the underlying disparities and advance drug development to enhance outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.